Skip to main content

Table 2 Baseline and disease characteristics for randomized, evaluable patients

From: Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Characteristic Arm A (cetuximab alone) Arm B (cetuximab + pemetrexed)
  N = 20 N = 23
Age (years)   
Median 62 55
Range (36–76) (45–75)
Sex: No. (%)   
Men 14 (70) 13 (57)
Women 6 (30) 10 (43)
Ethnicity: No. (%)   
White 13 (65) 17 (74)
African-American 7 (35) 5 (22)
Asian 0 (0) 1 (4)
Smoking history: No. (%)   
Current 7 (35) 6 (26)
Past 11 (55) 13 (57)
Never 2 (10) 2 (9)
Unknown 0 (0) 2 (9)
Histology: No. (%)   
Unspecified 7 (35) 9 (39)
Squamous 6 (30) 8 (35)
Adenocarcinoma 7 (35) 6 (26)